The respect i was talking about concerned board members here. But, i guess your mood swings make that pretty impossible.
Sorry if not politically correct enough for you. Talk about being a little sensitive? In business dealings, it is more than well known that the chinese will not let american companies into the chinese market without having full access to their technology. If they cant get it that way, they hack into multiple US companys and defense dept. computers to take IP. What a coincidence that their stealth fighter has same structure as ours The examples are endless. And on trade deals? I guess i will add that the chinese are cheaters as well as thieves.
So as my comment was about business, yes the chinese are thieves. And yes it will get much worse between the 2 countries. They are militarizing the islands in the S China Sea and working on bringing new Carriers into their growing Navel fleet. And yes, i have no respect for the Chinese or any American (Obama or you) who doesnt recognize the danger at hand.
So grow up Donk and keep the high minded, meaningless, platitudes to yourself.
Things may be changing.
Hollinger states, “It has been a long journey back to being the company I expected. I look forward to the day when I can see 10Ks and 10Qs posted and announce that HEC is once again in full compliance. I believe the HEC team is now strong enough to compete and grow the company into a competitive energy company. We can now supply 'turn-key' systems that can generate and store hydrogen for nearly any application.”
HEC has concentrated on “Time of Use” energy needs. We can supply power when the sun doesn’t shine or the wind doesn’t blow and do it without harming the environment. 175 nations so far have signed the Paris Climate Agreement. HEC can now help them all. HEC is looking at Southeast Asia, West Africa and US Military as the first three markets it could support
Hey donk, what happened to the respectful dialogue? The board was just starting to get interesting and now back to the same old. What a shame.
No breath holding here. The Lee's/China connection has no value in the rgrx stock price now. China always tries to steal the IP from american companies. They are never trusted partners. But, reminds me of the old Scln debate years ago, where scln was selling big amounts of their drug in china. At the time, there were many knockoff brands that went around the patents of scln, but the Chinese always preferred and paid up for the American version. The chinese may be thieves but they are not stupid, they want a product that has real quality control when it goes into their bodies. And SCLN to this day, with many knockoffs still around, sells a ton of product in China.
We do not know when the Hong Kong/Taiwan trial will begin enrollment of patients, although we have been recently communicating with Lee's regarding information and data transfer in preparation for a trial. Under this revised strategy, Lee's believes it should be able to begin a Phase 3 registration trial in China sooner rather than waiting on the production of T�4 in China before initiating a Phase 2b trial.
"We dont know when Honk Kong/Taiwan trial will start enrolling patients although we have been providing documents and data RECENTLY for their clinical activities."
They waited for recent results and are using to start soon.....imho
Just might make someone step up and place a 150+ number on BMRN. Company has been in the sights of big pharma for years. Maybe now they realize that BMRN will never be bought on the cheap. Could be the opening of the floodgate for bio takeouts
I cant get any details on the info like glaucome and osdi. They are keeping that to themselves. Why? I do not know. Maybe they dont have it or Koreans havent given it to JJ. Or maybe nothing there? But i agree more info is needed by rgrx...........and very soon.
Any news on glaucoma would rock the stock price much higher. Donk might say that maybe that isnt in the insiders interest just yet. Who knows?????????
Preserving the Ocular Surface
Protecting the integrity of the ocular surface while treating ocular conditions like glaucoma is undoubtedly the wave of the future.
There are a number of options for treating glaucoma, including medications with preservatives, preservative-free drugs and those with soft preservatives. Some literature has described the negative effects of preservatives, particularly benzalkonium chloride, in topical ophthalmic medications. However, the relevance of much of this work to clinical practice remains unclear, as BAK-containing preparations continue to find widespread use in the management of glaucoma and other ocular disorders, due largely to the preservative’s superior antimicrobial effectiveness.14Because of the difficulties associated with treating both glaucoma and OSD, however, it’s important to have a variety of treatment modalities available for patients with a history of OSD or for those who may develop symptoms of OSD during the course of their glaucoma therapy. Many treatment options, including punctal plugs, steroids and prescription therapies, are available to patients, although most patients can manage their symptoms with over-the-counter tear substitutes to temporarily relieve the clinical signs and symptoms associated with those diseases.
Protecting the integrity of the ocular surface while treating ocular conditions like glaucoma is undoubtedly the wave of the future. Eye drops with additional ocular-surface-protective properties should become a part of an ophthalmologist’s armamentarium for patients with ocular surface disorders, and potentially for all patients at risk for ocular surface diseases requiring long-term treatment with drops.
We know that tb4 can protect the ocular surface. If it also lowers pressure, it would be the first in class and make current valuation ridiculous. imho
Huge study with 16000 participants from 1/1/2010 to 12/30/12. The analysis and data collection took years and just now published. Results are what you might expect; higher levels of ozone and lower humidity levels associated with more cases and severity of dry eye. All participants in Korea.
This is very much of interest to the china market.
Obviously. koreans looking at this indication for years
It wont let me copy any more but can go to JAMA and see the entire abstract....its free and really shows how diligent the koreans are. They are into TB4 bigtime
Potential Importance of Ozone in the Association Between Outdoor Air Pollution and Dry Eye Disease in South Korea
Sung Ha Hwang, MD1; Yoon-Hyeong Choi, PhD2; Hae Jung Paik, MD, PhD1; Won Ryang Wee, MD, PhD3; Mee Kum Kim, MD, PhD3; #$%$ Hyun Kim, MD1
Dont know what shorts #'s really are here, but
Supreme Court Rules Against Brokerage Firms in Escala Short-Selling Case
DOW JONES & COMPANY, INC. 10:32 AM ET 5/16/2016
WASHINGTON -- The U.S. Supreme Court on Monday issued a procedural ruling against a group of financial firms fighting a lawsuit alleging they manipulated the market for shares of Escala Group Inc., a company removed from the Nasdaq nearly a decade ago.
The firms, including Bank of America Corp.'s Merrill Lynch and a UBS Group AG subsidiary, wanted the case heard in federal court, which is considered a friendlier venue for defendants in securities cases. Instead, the Supreme Court, in an opinion by Justice Elena Kagan, ruled unanimously that the case could proceed in New Jersey's state courts, the preferred venue for Escala founder Greg Manning and other shareholders who sued the firms.
The Escala shareholders alleged the securities brokers, lured by commissions, allowed their customers to engage in short sales of more Escala stock than actually existed for a small, lightly-traded company. The effect was to drive down the prices of the company's shares, the plaintiffs allege.
Good points on unnecessary placebo arm. FDA taking some serious heat on panel vote on srpt's drug for MD for boys. Srpt did not run a placebo arm and small trial so FDA refuses to approve, it seems. And this with a disease that kills everyone and a drug with no side effects that showed good improvement as told by MD experts in the field. What mother would put his child on a placebo??
Final vote the 26th on srpt. New FDA head under extreme pressure to do the right thing and overturn panel vote. If she does, it will mean a new kinder FDA and have positive implications for the whole sector.
Why does the obvious need to be stated in an SEC doc? Why dont all companies tell us who is in charge?
Only for vaso; that disfuctional entity run for the insiders only. But, cat fight at the top.
Nawchi, thats not cool at all, wishing someone cancer. You want to express your displeasure with JJ, that is fine and well deserved in many ways. But, that comment is way over the top.
"The Chief Operation Decision maker is the CEO."
Why would you need to put that in a 10Q? I could see if there was co-ceo's, but by definition the one ceo here(ma) is the decision maker. It leads one to believe that Castle might be taking a lead and Ma is seen as dead weight. Really, what does the guy do? Each division has its own head and they run each. The biggest one now is Netwolves. Castle should be running the whole show. Ma's 600k+ compensation is a big waste and just adds to the bloated 9.7 million(incredible) SG&A.
By the way, not only did Castle and Leiberman scam shareholders here out of 14.2 million on netwolves buy, but 6 directors of Vaso are collecting 9% a year on 2.2 million they lent to finance purchase. Sweet deal for them and plenty of cash flow to support as none of it ever gets to the shareholders. Just another example how vaso is run for the benefit of insiders ONLY.
Ma should be fired